
zzso is a highly potent and selective zzso zzso zzso zzso indicated for the prevention of zzso zzso and zzso Clinical trials have demonstrated zzso to be effective and well tolerated at a standard dose of 40 zzso or 3 zzso given zzso as a zzso zzso In this study, the efficacy and safety of zzso given as a zzso infusion was zzso A total of 21 patients, scheduled to undergo chemotherapy, received a single zzso zzso dose of zzso over 30 zzso completed at 1 h before chemotherapy zzso Patients were allowed two further zzso doses of zzso at 3 zzso within the zzso assessment zzso Changes from baseline values in vital signs were zzso prior to zzso administration and at 30 s as well as 1, 10, 15, 30 and 60 zzso after zzso zzso zzso zzso recordings were taken for 6 h prior to and 1 h after zzso No significant change was found in vital signs at 30 s or 1 zzso after zzso zzso There was a small but statistically significant fall in zzso blood pressure as compared with baseline and a zzso trend in zzso of a reduction in heart rate at 10 and 15 zzso No zzso zzso was recorded zzso that had not been present zzso None of these changes was considered to be clinically zzso The treatment was well zzso The most frequently reported adverse events were zzso zzso zzso 6) and headache zzso zzso zzso zzso plasma levels of zzso were within the range of zzso zzso except in one zzso The median values recorded for peak concentration zzso and area under the curve zzso were 195 zzso and zzso zzso h zzso zzso In conclusion, zzso at 3 zzso was shown to be safe and well tolerated when given as a zzso zzso infusion to patients receiving chemotherapy for zzso zzso 

